Leukemia Research
Volume 34, Issue 10 , Pages 1308-1313 , October 2010

Influence of high expression of Smac/DIABLO protein on the clinical outcome in acute myeloid leukemia patients

  • Agnieszka Pluta

      Affiliations

    • Department of Hematology, Medical University of Lodz, Copernicus Memorial Hospital, Ciolkowskiego 2 str, 93-510 Lodz, Poland
    • ,
  • Agata Wrzesien-Kus

      Affiliations

    • Department of Hematology, Medical University of Lodz, Copernicus Memorial Hospital, Ciolkowskiego 2 str, 93-510 Lodz, Poland
    • ,
  • Barbara Cebula-Obrzut

      Affiliations

    • Department of Experimental Hematology, Medical University of Lodz, Copernicus Memorial Hospital, Lodz, Poland
    • ,
  • Anna Wolska

      Affiliations

    • Department of Hematology, Medical University of Lodz, Copernicus Memorial Hospital, Ciolkowskiego 2 str, 93-510 Lodz, Poland
    • ,
  • Anna Szmigielska-Kaplon

      Affiliations

    • Department of Hematology, Medical University of Lodz, Copernicus Memorial Hospital, Ciolkowskiego 2 str, 93-510 Lodz, Poland
    • ,
  • Magdalena Czemerska

      Affiliations

    • Department of Hematology, Medical University of Lodz, Copernicus Memorial Hospital, Ciolkowskiego 2 str, 93-510 Lodz, Poland
    • ,
  • Piotr Pluta

      Affiliations

    • Department of Surgical Oncology, Medical University of Lodz, Copernicus Memorial Hospital, Lodz, Poland
    • ,
  • Tadeusz Robak

      Affiliations

    • Department of Hematology, Medical University of Lodz, Copernicus Memorial Hospital, Ciolkowskiego 2 str, 93-510 Lodz, Poland
    • ,
  • Piotr Smolewski

      Affiliations

    • Department of Experimental Hematology, Medical University of Lodz, Copernicus Memorial Hospital, Lodz, Poland
    • ,
  • Agnieszka Wierzbowska

      Affiliations

    • Department of Hematology, Medical University of Lodz, Copernicus Memorial Hospital, Ciolkowskiego 2 str, 93-510 Lodz, Poland
    • Corresponding Author InformationCorresponding author. Tel.: +48 426895191; fax: +48 426895192.

Received 5 November 2009 ,Revised 29 November 2009 ,Accepted 29 November 2009.

References 

  1. Gudgin E, Huntly B. Acute myeloid leukemia biology and leukemia stem cells. In: Hematology education: the education program for the annual congress of the European Hematology Association, vol. 3. 2009;p. 17–23
  2. Haferlach T. Molecular genetics pathways as therapeutic targets in acute myeloid leukemia. Hematol Am Soc Hematol Educ Prog. 2008;400–411
  3. Hegde R, Srinivasula SM, Zhang Z, Wassell R, Mukattash R, Cilenti L, et al. Identification of Omi/HtrA2 as a mitochondrial apoptotic serine protease that disrupts inhibitor of apoptosis protein–caspase interaction. J Biol Chem. 2002;277:432–438
  4. Martins LM, Iaccarino I, Tenev T, Gschmeissner S, Totty NF, Lemoine NR, et al. The serine protease Omi/HtrA2 regulates apoptosis by binding XIAP through a reaper-like motif. J Biol Chem. 2002;277:439–444
  5. Verhagen AM, Silke J, Ekert PG, Pakusch M, Kaufmann H, Connolly LM, et al. HtrA2 promotes cell death through its serine protease activity and its ability to antagonize inhibitor of apoptosis proteins. J Biol Chem. 2002;277:445–454
  6. Leaman DW, Chawla-Sarkar M, Vyas K, Reheman M, Tamai K, Toji S, et al. Identification of X-linked inhibitor of apoptosis-associated factor-1 as an interferon-stimulated gene that augments TRAIL Apo2L-induced apoptosis. J Biol Chem. 2002;277:28504–28511
  7. Yan N, Shi Y. Mechanisms of apoptosis through structural biology. Annu Rev Cell Dev Biol. 2005;21:35–56
  8. Verhagen AM, Ekert PG, Pakusch M, Silke J, Connolly LM, Reid GE, et al. Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins. Cell. 2000;102:43–53
  9. Du C, Fang M, Li Y, Li L, Wang X. Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell. 2000;102:33–42
  10. Vince JE, Wong WW, Khan N, Feltham R, Chau D, Ahmed AU, et al. IAP antagonists target cIAP1 to induce TNFalpha-dependent apoptosis. Cell. 2007;131:682–693
  11. Wang L, Du F, Wang X. TNF-alpha induces two distinct caspase-8 activation pathways. Cell. 2008;133:693–703
  12. Fu J, Jin Y, Arend LJ. Smac3, a novel Smac/DIABLO splicing variant, attenuates the stability and apoptosis-inhibiting activity of X-linked inhibitor of apoptosis protein. J Biol Chem. 2003;278:52660–52672
  13. Jia L, Patwari Y, Kelsey SM, Srinivasula SM, Agrawal SG, Alnemri ES, et al. Role of Smac in human leukaemic cell apoptosis and proliferation. Oncogene. 2003;22:1589–1599
  14. Wrzesień-Kuś A, Smolewski P, Sobczak-Pluta A, Wierzbowska A, Robak T. The inhibitor of apoptosis protein family and its antagonists in acute leukemias. Apoptosis. 2004;9:705–715
  15. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, et al. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med. 1985;103:620–625
  16. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;30:937–951
  17. Holowiecki J, Grosicki S, Kyrcz-Krzemien , Kuliczkowski K, Skotnicki A, Hellmann A, et al. Addition of cladribine to the standard daunorubicine–cytarabine (DA 3+7) remission induction protocol (DAC) contrary to adjunct of fludarabine (DAF) improves the overall survival in untreated adults with acute myeloid leukemia aged up to 60Y: a multicenter, randomized, phase III PALG AML 1/2004 DAF/DAC/DA study in 673 patients. Blood. 2008;112:133;[Abstract]
  18. Cheson BD, Bennett JM, Kopecky KJ, Büchner T, Willman CL, Estey EH, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol. 2003;21:4642–4649[Erratum in: J Clin Oncol 2004;22:576]
  19. Yoo NJ, Kim HS, Kim SY, Park WS, Park CH, Jeon HM, et al. Immunohistochemical analysis of Smac/DIABLO expression in human carcinomas and sarcomas. APMIS. 2003;111:382–388
  20. Endo K, Kohnoe S, Watanabe A, Tashiro H, Sakata H, Morita M, et al. Clinical significance of Smac/DIABLO expression in colorectal cancer. Oncol Rep. 2009;21:351–355
  21. Yan Y, Mahotka C, Heikaus S, Shibata T, Wethkamp N, Liebmann J, et al. Disturbed balance of expression between XIAP and Smac/DIABLO during tumour progression in renal cell carcinomas. Br J Cancer. 2004;4(91):1349–1357
  22. Bao ST, Gui SQ, Lin MS. Relationship between expression of Smac and Survivin and apoptosis of primary hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int. 2006;5:580–583
  23. Anguiano-Hernandez YM, Chartier A, Huerta S. Smac/DIABLO and colon cancer. Anticancer Agents Med Chem. 2007;7:467–473
  24. Ren Y, Akyurek N, Schlette E, Rassidakis GZ, Medeiros LJ. Expression of Smac/DIABLO in B-cell non-Hodgkin and Hodgkin lymphomas. Hum Pathol. 2006;37:1407–1413
  25. Kempkensteffen C, Hinz S, Christoph F, Krause H, Magheli A, Schrader M, et al. Expression levels of the mitochondrial IAP antagonists Smac/DIABLO and Omi/HtrA2 in clear-cell renal cell carcinomas and their prognostic value. J Cancer Res Clin Oncol. 2008;134:543–550
  26. Mizutani Y, Nakanishi H, Yamamoto K, Li YN, Matsubara H, Mikami K, et al. Downregulation of Smac/DIABLO expression in renal cell carcinoma and its prognostic significance. J Clin Oncol. 2005;23:448–454
  27. Heerema-McKenney A, Arber DA. Acute myeloid leukemia. Hematol Oncol Clin N Am. 2009;23:633–654
  28. Mrózek K. Cytogenetic, molecular genetic, and clinical characteristics of acute myeloid leukemia with a complex karyotype. Semin Oncol. 2008;35:365–377
  29. Klepin HD, Balducci L. Acute myelogenous leukemia in older adults. Oncologist. 2009;14:222–232

PII: S0145-2126(09)00552-9

doi: 10.1016/j.leukres.2009.11.030

Leukemia Research
Volume 34, Issue 10 , Pages 1308-1313 , October 2010

Article Tools

* Image Usage & Resolution